Latest news and press releases about Cardio Diagnostics Holdings, Inc. (CDIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Price
| Price | $2.00 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.80 |
| EV / EBITDA | -0.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -93.19% |
| Return on Invested Capital | -84.55% |
| Return on Assets | -83.67% |
| Gross Margin | -555.03% |
| Operating Margin | -44690.68% |
| Net Margin | -44771.83% |
Related companies: ADIL · ADXN · BCDA · BCLI · CELZ · IBO · MTNB
Explore sector: Healthcare · Biotechnology
More sections of CDIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks